Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from ...

27
Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from www.biostat.wisc.edu/training/courses/542slides/09- qol.pdf

Transcript of Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from ...

Page 1: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Quality of Life Assessment

in Clinical Trials

Elizabeth Garrett-Mayer

Some slides adapted from www.biostat.wisc.edu/training/courses/542slides/09-

qol.pdf

Page 2: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Aside: MIXED procedure “Mixed” effects model in SAS Includes both fixed and random effects Fixed effects

Time Treatment

Random effects Person-specific coefficients

Commonly seen Estimate a common slope over time Allow each individual to has his/her own intercept

Page 3: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

0 5 10 15 20

-50

51

01

5

TIME

RE

SP

ON

SE

Page 4: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Why are we interested in Quality of Life (QOL)?

The FDA has stated that efficacy with respect to overall survival and/or improvements in QOL might provide the basis for drug approval.

Shaughnessy JA, Wittes RE, Burke G et al.Commentary concerning demonstration of safety and efficacy ofInvestigational anticancer agents in clinical trials.Journal of Clinical Oncology 1991 (9) 2225-32

Page 5: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Measuring QOL

Happy Miserable

How are you feeling today?

Page 6: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

What is QoL? WHO: “Health is not only the absence of

infirmity and disease, but also a state of physical, mental and social well-being.”

Multiple domains include: Physical, cognitive, emotional and social functioning, pain, sexual functioning, health perceptions, and symptoms about nausea and fatigue

Fundamental Principle: QoL IS ASSESSED BY THE PATIENT

Page 7: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

QoL Definition depends on context:

Cancer vs. MI vs. hypertension Early instruments for measuring QoL were

disease-specific Later instruments, “general health status”

POMS = Profile of Mood SIP = Sickness Impact Profile

Difficulties with concept No agreement on definition Lack of standardized measures

Page 8: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

QoL One definition (Levine and Croog) has two components:

Functioning Social (major component): get along with family and

friends Physical: perform daily activities Emotional: stability and self-control Intellectual: decision-making ability

Perceptions Life satisfaction: sense of well-being Health Status: compared to others

Page 9: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Factors influencing QoL Interventions/Treatment Disease Processes Labeling: diagnosis brings on ‘change’ Concomitant Care Non-related life events (e.g. death in the

family)

Page 10: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Rationale in Clinical Trials

QOL assesses effect of intervention/treatment Primary response (treatment improves symptoms?) Side effects (treatment toxic?) Economic aspects (low risk/cost of treatment but high

benefit?) Another setting: Treatment for pain

Primary response (pain lessened?) Side effects (interact with disease? Other side effects?) Economic aspects

Page 11: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Data Collection Data collection can add measurement error or

bias Mode: self-administered vs. interview

Self-admin: Reading ability, fine-motor skills Interview: Hearing problems, age/gender/ethnicity

sensitivity, training of interviewer Either: language

Content Instrument validity, sensitivity, specificity Sensitivity of questions Frame of reference (cognitive skills, privacy, cultural

background) Source(s)

Patient vs family vs health care provider

Page 12: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Assessing QoL Hardest part! Determine QoL objective Choose instrument to measure QoL

Reliable, valid, responsive, feasible Global measures, disease-specific measures,

symptom checklists Select assessment time points Develop analysis plan

Page 13: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Choosing your instrument Off-the-shelf (i.e. general) instruments

Designed to distinguish sickness from wellness May not be sensitive to particular aspect of a

given trial May not be validated or “normed” in

population being tested May ask silly questions for trial population May take long time to complete May impact negatively on compliance

Page 14: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Choosing your instrument “Tailor Made” Instruments

Quick and simple Standardized but targeted to disease Validated, normed to trial population Select subsets of off-the-shelf instruments

Home-Made Instruments Often designed by graduate student or

comparable Often too long Often not validated or ‘normed’ or field tested

in the patient population of interest

Page 15: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

a. CARES-SF (Schag 1991) - 59 item scale which measures rehabilitation and quality of life in patients with cancer. This has been modified to the HIV Overview of Problems Evaluation Systems (HOPES, Schag 1992)

b. City of Hope Quality of Life, Cancer Patient Version (Ferrell 1995) – a 41 item ordinal scale representing the four domains of quality of life including physical well being, psychological well being, and spiritual well being.

c. Daily Diary Card-QOL (Gower 1995) - a self-administered card for use in cancer clinical trials that has been shown to demonstrate short-term changes in quality of life related to symptoms induced by chemotherapy.

d. EORTC QOL-30 (Aaronson 1993) - this instrument is composed of modules to assess quality of life for specific cancers in clinical trials. The current instrument is 30 items with physical function, role function, cognitive function, emotional function, social function, symptoms, and financial impact.

e. FACT-G (Cella 1993) – a 33 item scale developed to measure quality of life in patients undergoing cancer treatment.

f. FLIC (Finkelstein 1988) – a 22 item instrument which measures quality of life in the following domains: physical/occupational function, psychological state, sociability, and somatic discomfort. This scale was originally proposed as an adjunct measure to cancer clinical trials.

g. Southwest Oncology Group Quality of Life Questionnaire (Moinpour 1990) – a scale developed for cancer patients incorporating questions from various function, symptoms, and global quality of life measures.

Page 16: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Measurement Look for measures that are proven to be

VALID RELIABLE

Validity: does measure actually measure the construct it is intended to measure?

Reliability: how much close is does our measure get to the “true” score? (ranges from 0 to 1)

Page 17: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Measurement RELIABILITY AND VALIDITY DEPEND ON THE

SAMPLE TO WHICH YOUR MEASURE IS APPLIED! Example:

the FACT-G has been shown to have reliability of in 0.87 in Americans undergoing chemotherapy (Cella)

Is it still a reliable measure in Japanese men with esophageal cancer?

Is it a reliable measure in Korean women with breast cancer?

If a measure is to be applied to a different population from which it has been validated on, it needs to be re-assessed.

Page 18: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Measurement What is the big deal if the reliability is lower in my

sample? Low reliability = Poor measure Low reliability also implies poor validity. Think of these scales as “surrogate markers” of

quality of life Would you use surrogate markers that you KNEW

were only weakly related to the true outcome of interest?

If reliability is low, then you are not measuring what you are trying to measure.

Look for reliabilities above 0.75

Page 19: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Measurement What about validity in new population?

The same items/questions may mean different things to different patient populations or cultures

For some latent variables (e.g. mental disorders), the variable of interest manifests itself differently in different cultures or population subgroups.

Translations into different languages can affect results dramatically

If there are items in the scale that are irrelevant for your patient population, then you are compromising your validity by including them.

Page 20: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Analytic Issues

“Measurement” QOL measured by multiple indicators Need validated overall ‘score’ Or, can use fancier multivariate methods

Usually, treat ‘score’ as observed level of QoL and proceed with analysis.

Problems: ‘score’ is often not a valid measure of QoL in

the patient population Score tends to be fraught with measurement

error (reliability tells you about this)

Page 21: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Analytic Issues ATAC study:

Used FACT-G and FACT-B. Simply added up the responses to each item

(but that is shown to be valid and reliable) Treats each item as “exchangeable:” assumes

each item is equally sensitive to changes in QoL

Alternative: develop model to weight each item relative to how informative it is about QoL (latent variable methods…..).

Page 22: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Latent Variables QoL is, by definition, a “latent variable:” it cannot

be directly measured. We measure it using “symptoms” of QoL Statistical methods help us make inference about

state of QoL via the symptoms. Develop models/scales for measuring QoL We can maximize reliability and evaluate validity.

Issues to consider: What if our “symptoms” are not tapping into QoL like we

think? What if patients’ perceptions of the questions we ask are

different? How can we find out about these things????

Page 23: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

QualityOf

Life

Have you felt

nauseated?

Have you hadproblemssleeping?

Have you had pain?

Have you lacked

appetite?

Have you felt

depressed?

Latent Variable Depiction

Page 24: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Other latent variables in medical research

Pain Mental disorders

Depression Schizophrenia Autism

Mobility/Function (gerontology) Arthritis

Page 25: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

Other QOL issues Often interested in whether or not survival with

poor quality of life is better than death without suffering.

“QALY”= Quality Adjusted Life Years Example:

Cancer: many patients would rather not get toxic therapies and have more enjoyable end of life

The general idea is to down-weight time spent in periods of poor quality of life.

Methodologically challenging: How to determine the weights? Different settings might need different weights.

Page 26: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

QTWIST: Quality-Adjusted Time Without Symptoms of disease and Toxicity.

Quality Adjusted Survival

Evaluate therapies based on both quantity and quality of life through survival analysis

Based on QALYs. Define QOL health states, including

one with good health (minimal symptoms).

Patients progress through health states and never back-track.

Partition the area under the Kaplan-Meier Curve and calculate the average time spent in each clinical health state.

Compare treatment regimens using weighted sums durations, weights are utility based.

Example: 5 year survival

0 6 1 0 8 2 0 6 1 0 2 1 3. . . . 3 adjusted years of life

Compare the average QTWIST in two treatment groups.Could be that on treatment A, people live longer, but QOL is worse.

Quality of Life for Individual

Page 27: Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from  qol.pdf.

References: www.biostat.wisc.edu/training/courses/542slides/09-qol.pdf

Fairclough and Gelber, “Quality of Life: Statistical Issues and Analysis.” From Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition, ed. B. Spiker. 1996.